Abstract
Aberrant DNA replication is one of the driving forces behind oncogenesis. Furthermore, minichromosome maintenance complex component 3 (MCM3) serves an essential role in DNA replication. Therefore, in the present study, the diagnostic and prognostic value of MCM3 and its interacting proteins in hepatocellular carcinoma (HCC) were investigated. By utilizing The Cancer Genome Atlas (TCGA) database, global MCM3 mRNA levels were assessed in HCC and normal liver tissues. Its effects were further analyzed by reverse transcription-quantitative PCR (RT-qPCR), western blotting and immunohistochemistry in 78 paired HCC and adjacent tissues. Functional and pathway enrichment analyses were performed using the Search Tool for the Retrieval of Interacting Genes database. The expression levels of proteins that interact with MCM3 were also analyzed using the TCGA database and RT-qPCR. Finally, algorithms combining receiver operating characteristic (ROC) curves were constructed using binary logistic regression using the TCGA results. Increased MCM3 mRNA expression with high $\alpha$-fetoprotein levels and advanced Edmondson-Steiner grade were found to be characteristic of HCC. Survival analysis revealed that high MCM3 expression was associated with poor outcomes in patients with HCC. In addition, MCM3 protein expression was associated with increased tumor invasion in HCC tissues. MCM3 and its interacting proteins were found to be primarily involved in DNA replication, cell cycle and a number of binding processes. Algorithms combining ROCs of MCM3 and its interacting proteins were found to have improved HCC diagnosis ability compared with MCM3 and other individual diagnostic markers. In conclusion, MCM3 appears to be a promising diagnostic biomarker for HCC. Additionally, the present study provides a basis for the multi-gene diagnosis of HCC using MCM3.
Introduction
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide, largely due to late-stage diagnosis and high recurrence rates. While markers like $\alpha$-fetoprotein (AFP) are commonly used in the clinic, they often lack the sensitivity and specificity required for reliable early detection or precise prognosis.
The machinery of DNA replication is a central hallmark of cancer development. Specifically, the MCM complex—a hexameric protein group—is essential for unwinding DNA during the G1/S transition. While MCM3 was known to be overexpressed in several malignancies, its specific diagnostic utility and its relationship with its "interactome" in HCC remained poorly defined. This study aims to evaluate MCM3 as a potent diagnostic and prognostic biomarker for HCC, exploring its synergistic potential with interacting proteins.
Methods
The study employed a dual-track approach, combining large-scale bioinformatics with bench-top validation:
- Data Mining: Analysis of mRNA expression and clinical data from The Cancer Genome Atlas (TCGA), comparing 363 HCC samples against 50 normal liver samples.
- Clinical Validation: Validation in 78 paired HCC and adjacent tissues from a Chinese cohort using RT-qPCR, Western blotting, and Immunohistochemistry (IHC).
- Network Analysis: Mapping of a Protein-Protein Interaction (PPI) network using the STRING database and Cytoscape to identify MCM3’s functional partners.
- Predictive Modeling: Development of multi-gene diagnostic models using binary logistic regression, evaluated via ROC curves and Area Under the Curve (AUC) metrics.
Results
MCM3 Expression and Clinical Correlation
MCM3 mRNA and protein levels were significantly elevated in HCC tissues compared to normal liver tissues. IHC staining revealed that MCM3 proteins are primarily concentrated in the nuclei of tumor cells, reinforcing its role in active, uncontrolled DNA replication. High MCM3 expression correlated with advanced Edmondson-Steiner grades and increased tumor invasion ($P=0.032$).
Prognostic and Diagnostic Value
Survival analysis demonstrated that patients with high MCM3 expression had significantly poorer Overall Survival (OS) and Recurrence-Free Survival (RFS) compared to those with low expression.
In terms of diagnostic performance, MCM3 alone showed an impressive AUC of 0.932, with a sensitivity of 85.4% and specificity of 92%.
The study further identified that MCM3's diagnostic power increases when analyzed alongside its partners: MCM2, MCM5, CHK1, and DHX9. Multi-gene models were even more robust; for instance, a model combining MCM2, MCM3, and MCM5 achieved an AUC of 0.989, providing nearly perfect discrimination between cancerous and healthy tissue.
Discussion and Conclusion
MCM3 acts as a regulatory hub in the G1/S transition and DNA duplex unwinding. Its consistent overexpression across different cohorts (TCGA and local) underscores its reliability as a biomarker. However, discrepancies between datasets regarding correlation with AFP levels suggest that ethnic diversity and sample size may influence biomarker manifestation.
While this study establishes a strong correlation between MCM3 and tumor invasion, the exact biochemical pathways through which MCM3 promotes cell migration require further elucidation. Future work should focus on prospective, large-scale clinical trials to confirm the real-world utility of these multi-gene diagnostic algorithms. In conclusion, MCM3 is a robust diagnostic and prognostic marker for HCC, offering a new avenue for early detection and personalized management of liver cancer.
Summary updated